Prevention of bone loss by percutaneous estradiol implants in ovariectomized rats

Keiko Yamamura, Hisashi Iwata, Takashi Osada, Kohji Yano, Toshihisa Yotsuyanagi, Toshitaka Nabeshima

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This study was conducted to investigate whether hydroxyapatite (HAP) is appropriate as a percutaneous drug carrier for estradiol (E2) for the suppression of bone loss. Ten‐week‐old female Sprague–Dawley rats were subjected either to bilateral ovariectomy (OVX) or to sham surgery (control). Ovariectomized rats were implanted percutaneously with E2‐HAP disks containing low, medium or high doses of estradiol (50, 250, or 500 μg E2/rat, respectively). Ovariectomized rats without implant and OVX rats implanted only with HAP served as additional controls. All rats were sacrificed 90 days after surgery. At the end of the experiment, bone mineral density of the lumbar spine was measured by dual energy X‐ray absorption, and serum E2 was assayed by radioimmunoassay. The bone mineral density of OVX and HAP‐treated OVX rats decreased by 18% compared to sham surgery rats, but decreased by only 13, 7, and 3% in rats treated with 50, 250, and 500 μg E2/rat, respectively. The in vitro release of E2 from E2‐HAP devices was determined by an HPLC method. Estradiol release from the HAP devices followed almost a zero‐order kinetics. Estradiol remained intact in E2‐HAP implants for up to six months when stored at 5, 25, and 40°C. This study indicates that E2‐HAP implants are effective in suppressing bone loss in the spine of OVX rats in a dose‐dependent manner. © 1995 John Wiley & Sons, Inc.

Original languageEnglish
Pages (from-to)1249-1253
Number of pages5
JournalJournal of Biomedical Materials Research
Volume29
Issue number10
DOIs
Publication statusPublished - 01-01-1995
Externally publishedYes

Fingerprint

Rats
Estradiol
Bone
Durapatite
Hydroxyapatite
Surgery
Minerals
Drug Carriers
Kinetics

All Science Journal Classification (ASJC) codes

  • Biomaterials
  • Biomedical Engineering

Cite this

Yamamura, Keiko ; Iwata, Hisashi ; Osada, Takashi ; Yano, Kohji ; Yotsuyanagi, Toshihisa ; Nabeshima, Toshitaka. / Prevention of bone loss by percutaneous estradiol implants in ovariectomized rats. In: Journal of Biomedical Materials Research. 1995 ; Vol. 29, No. 10. pp. 1249-1253.
@article{5ff13a3b724f446e9c1d73464d8eab26,
title = "Prevention of bone loss by percutaneous estradiol implants in ovariectomized rats",
abstract = "This study was conducted to investigate whether hydroxyapatite (HAP) is appropriate as a percutaneous drug carrier for estradiol (E2) for the suppression of bone loss. Ten‐week‐old female Sprague–Dawley rats were subjected either to bilateral ovariectomy (OVX) or to sham surgery (control). Ovariectomized rats were implanted percutaneously with E2‐HAP disks containing low, medium or high doses of estradiol (50, 250, or 500 μg E2/rat, respectively). Ovariectomized rats without implant and OVX rats implanted only with HAP served as additional controls. All rats were sacrificed 90 days after surgery. At the end of the experiment, bone mineral density of the lumbar spine was measured by dual energy X‐ray absorption, and serum E2 was assayed by radioimmunoassay. The bone mineral density of OVX and HAP‐treated OVX rats decreased by 18{\%} compared to sham surgery rats, but decreased by only 13, 7, and 3{\%} in rats treated with 50, 250, and 500 μg E2/rat, respectively. The in vitro release of E2 from E2‐HAP devices was determined by an HPLC method. Estradiol release from the HAP devices followed almost a zero‐order kinetics. Estradiol remained intact in E2‐HAP implants for up to six months when stored at 5, 25, and 40°C. This study indicates that E2‐HAP implants are effective in suppressing bone loss in the spine of OVX rats in a dose‐dependent manner. {\circledC} 1995 John Wiley & Sons, Inc.",
author = "Keiko Yamamura and Hisashi Iwata and Takashi Osada and Kohji Yano and Toshihisa Yotsuyanagi and Toshitaka Nabeshima",
year = "1995",
month = "1",
day = "1",
doi = "10.1002/jbm.820291012",
language = "English",
volume = "29",
pages = "1249--1253",
journal = "Journal of Biomedical Materials Research",
issn = "0021-9304",
publisher = "Heterocorporation",
number = "10",

}

Prevention of bone loss by percutaneous estradiol implants in ovariectomized rats. / Yamamura, Keiko; Iwata, Hisashi; Osada, Takashi; Yano, Kohji; Yotsuyanagi, Toshihisa; Nabeshima, Toshitaka.

In: Journal of Biomedical Materials Research, Vol. 29, No. 10, 01.01.1995, p. 1249-1253.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevention of bone loss by percutaneous estradiol implants in ovariectomized rats

AU - Yamamura, Keiko

AU - Iwata, Hisashi

AU - Osada, Takashi

AU - Yano, Kohji

AU - Yotsuyanagi, Toshihisa

AU - Nabeshima, Toshitaka

PY - 1995/1/1

Y1 - 1995/1/1

N2 - This study was conducted to investigate whether hydroxyapatite (HAP) is appropriate as a percutaneous drug carrier for estradiol (E2) for the suppression of bone loss. Ten‐week‐old female Sprague–Dawley rats were subjected either to bilateral ovariectomy (OVX) or to sham surgery (control). Ovariectomized rats were implanted percutaneously with E2‐HAP disks containing low, medium or high doses of estradiol (50, 250, or 500 μg E2/rat, respectively). Ovariectomized rats without implant and OVX rats implanted only with HAP served as additional controls. All rats were sacrificed 90 days after surgery. At the end of the experiment, bone mineral density of the lumbar spine was measured by dual energy X‐ray absorption, and serum E2 was assayed by radioimmunoassay. The bone mineral density of OVX and HAP‐treated OVX rats decreased by 18% compared to sham surgery rats, but decreased by only 13, 7, and 3% in rats treated with 50, 250, and 500 μg E2/rat, respectively. The in vitro release of E2 from E2‐HAP devices was determined by an HPLC method. Estradiol release from the HAP devices followed almost a zero‐order kinetics. Estradiol remained intact in E2‐HAP implants for up to six months when stored at 5, 25, and 40°C. This study indicates that E2‐HAP implants are effective in suppressing bone loss in the spine of OVX rats in a dose‐dependent manner. © 1995 John Wiley & Sons, Inc.

AB - This study was conducted to investigate whether hydroxyapatite (HAP) is appropriate as a percutaneous drug carrier for estradiol (E2) for the suppression of bone loss. Ten‐week‐old female Sprague–Dawley rats were subjected either to bilateral ovariectomy (OVX) or to sham surgery (control). Ovariectomized rats were implanted percutaneously with E2‐HAP disks containing low, medium or high doses of estradiol (50, 250, or 500 μg E2/rat, respectively). Ovariectomized rats without implant and OVX rats implanted only with HAP served as additional controls. All rats were sacrificed 90 days after surgery. At the end of the experiment, bone mineral density of the lumbar spine was measured by dual energy X‐ray absorption, and serum E2 was assayed by radioimmunoassay. The bone mineral density of OVX and HAP‐treated OVX rats decreased by 18% compared to sham surgery rats, but decreased by only 13, 7, and 3% in rats treated with 50, 250, and 500 μg E2/rat, respectively. The in vitro release of E2 from E2‐HAP devices was determined by an HPLC method. Estradiol release from the HAP devices followed almost a zero‐order kinetics. Estradiol remained intact in E2‐HAP implants for up to six months when stored at 5, 25, and 40°C. This study indicates that E2‐HAP implants are effective in suppressing bone loss in the spine of OVX rats in a dose‐dependent manner. © 1995 John Wiley & Sons, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0029380448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029380448&partnerID=8YFLogxK

U2 - 10.1002/jbm.820291012

DO - 10.1002/jbm.820291012

M3 - Article

VL - 29

SP - 1249

EP - 1253

JO - Journal of Biomedical Materials Research

JF - Journal of Biomedical Materials Research

SN - 0021-9304

IS - 10

ER -